Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
36.07
+0.81 (2.30%)
Aug 13, 2025, 4:00 PM - Market closed
Revolution Medicines Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
534
Market Cap
6.74B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | 11.58M | -23.80M | -67.27% |
Dec 31, 2022 | 35.38M | 5.99M | 20.38% |
Dec 31, 2021 | 29.39M | -13.59M | -31.62% |
Dec 31, 2020 | 42.98M | -7.06M | -14.10% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
RVMD News
- 7 days ago - Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress - GlobeNewsWire
- 14 days ago - Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025 - GlobeNewsWire
- 20 days ago - Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor - GlobeNewsWire
- 21 days ago - Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib - GlobeNewsWire
- 5 weeks ago - Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates - GlobeNewsWire
- 6 weeks ago - Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors - GlobeNewsWire
- 6 weeks ago - Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors - Business Wire